Accepted Manuscript Intradural Juvenile Xanthogranuloma with Involvement of Multiple Nerve Roots. A Case Report and Review of the Literature Cody Wolfe, BS;, Tarek Y. El Ahmadieh, MD;, Salah G. Aoun, MD;, Awais Z. Vance, MD;, Kimmo J. Hatanpaa, MD, PhD;, Bryan Wohlfeld, MD PII:
S1878-8750(18)31753-4
DOI:
10.1016/j.wneu.2018.07.273
Reference:
WNEU 8838
To appear in:
World Neurosurgery
Received Date: 6 June 2018 Revised Date:
29 July 2018
Accepted Date: 30 July 2018
Please cite this article as: Wolfe C, El Ahmadieh TY, Aoun SG, Vance AZ, Hatanpaa KJ, Wohlfeld B, Intradural Juvenile Xanthogranuloma with Involvement of Multiple Nerve Roots. A Case Report and Review of the Literature, World Neurosurgery (2018), doi: 10.1016/j.wneu.2018.07.273. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT 1 1
Intradural Juvenile Xanthogranuloma with Involvement of Multiple Nerve Roots. A Case
2
Report and Review of the Literature 1
3
CODY WOLFE, B.S.; TAREK Y. EL AHMADIEH, M.D.;2 SALAH G. AOUN, M.D.;2 AWAIS Z. VANCE, M.D.; 2
4
KIMMO J. HATANPAA, M.D., PHD;3 BRYAN WOHLFELD, M.D.2*
6
1
7
School of medicine, Dallas, Texas, USA
8
2
9
Dallas, Texas, USA
RI PT
5
Department of neurological surgery, The University of Texas Southwestern Medical Center,
10
3
11
USA
SC
Department of neurological surgery, The University of Texas Southwestern Medical Center,
Department of pathology, The University of Texas Southwestern Medical Center, Dallas, Texas,
M AN U
12 13 14 15 16
18 19
TE D
17
*corresponding author.
21
Correspondence to:
[email protected].
22
Department of Neurological Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd.
23
Dallas, TX 75390. Phone: 214-648-9317
25 26 27
AC C
24
EP
20
Conflict of interest: The authors have no disclosures related to the content of this manuscript.
Disclosure of funding: none
28 29
Keywords: Juvenile Xanthogranuloma, thoracolumbar tumors, spinal lesions, inflammation,
30
inflammatory spine disease
31
ACCEPTED MANUSCRIPT 2 Abstract
33
Background: Juvenile Xanthogranuloma is a rare, non-Langerhan’s cell histiocytic disorder that
34
primarily presents as multiple cutaneous lesions in young males. Solitary lesions in the spinal
35
column are a particularly rare presentation of this disease, and CNS involvement can portend a
36
poor prognosis. This report highlights an unusual case of an adult woman with an unresectable
37
JXG of the lumbar spine. A review of the published cases of thoracolumbar JXG and the current
38
state of the literature in regard to diagnosis and treatment is presented.
39
Case Description: A 28-year-old woman presented with back pain and worsening lower
40
extremity pain, numbness and weakness. MRI demonstrated an enhancing lumbar mass, but at
41
the time of surgery, no discrete mass was identified. Multiple roots were grossly enlarged, and
42
electrical stimulation identified the L4 root as the most abnormal. Despite an attempt to debulk,
43
the majority of the mass could not be safely removed. The patient had incomplete improvement
44
of symptoms post-operatively but elected to forgo chemotherapy. Three-month follow-up
45
imaging showed active lumbar spinal disease, and imaging and follow up at 27-months has
46
revealed no changes. Her symptoms have been satisfactorily controlled with conservative
47
therapy.
48
Conclusions: Juvenile Xanthogranuloma of the spine is a rare disease who’s nonspecific clinical
49
and radiographic findings can make difficult to diagnose and dictates the use of
50
immunohistochemical staining. If possible, total surgical resection offers the greatest outcomes,
51
but other modalities such as chemotherapy may be viable alternatives or adjuvants.
54 55 56 57 58 59 60 61 62
SC
M AN U
TE D
EP
53
AC C
52
RI PT
32
ACCEPTED MANUSCRIPT 3 63 64
Background: Juvenile Xanthogranuloma (JXG) is a rare, non-Langerhan’s cell histiocytic disorder
66
caused by proliferation of cells derived from dermal dendrocytes.1 It is primarily a disease of
67
early life, with most cases occurring at birth or during the first year of life.1-6 It is more
68
commonly seen in males,1,3,4 who typically present with multiple cutaneous lesions. Early
69
description of this disorder has been credited to Rudolf Virchow,7 and reports of these lesions in
70
the literature date back to Adamson in 1905 8 and McDonagh in 19129 before the term JXA was
71
introduced in 1954 by Helwig and Hackney,10 Initially noted to be a cutaneous disorder, the most
72
common presentation of JXG is as benign nodules located on the head, neck and trunk.1 Less
73
common presentations of JXG include multiple and systemic lesions that may be aggressive and
74
lethal.1-3,11-13 Extracutaneous sites of JXG have been reported in the liver, spleen, lungs, kidneys,
75
eyes, subcutaneous soft tissue, bones, and both peripheral (PNS) and central nervous systems
76
(CNS).1,2,4,7,11,14,15
M AN U
SC
RI PT
65
JXG of the CNS typically follows an indolent course, although rare cases of clinically
78
aggressive JXG have been reported.2 Treatment strategies vary and may depend on resectability
79
of the tumor, as complete resection may be curative. Poorly accessible tumors, widespread or
80
progressive disease may require aggressive systemic therapy which may include corticosteroids
81
and vinca alkaloids and/or radiation.16 However, the efficacy of treatments has not clearly been
82
established, and there is therefore no accepted protocol for treatment of JXG involving the CNS.
TE D
77
Herein, we report on a patient who presented with a solitary lumbar mass in the absence
84
of cutaneous disease that was histologically revealed to be JXG. The mass was not amenable to
85
total resection and chemotherapy was declined. The surgical operation, histology, and follow-up
86
treatment plan are reported. Reports of thoracolumbar JXG cases are reviewed and the relevant
87
literature is discussed.
89 90
AC C
88
EP
83
Case Description:
91
A 28-year-old woman presented with a one-year history of back and lower extremity
92
pain, worsening numbness in legs and weakness in the left foot. Magnetic resonance imaging
93
(MRI) of the lumbar spine demonstrated an enhancing mass from L3 to L5 that appeared to fill
ACCEPTED MANUSCRIPT 4 94
the foramen at L4/5 on the left (Figure 1A-D). The differential diagnoses included
95
ependymoma, and peripheral nerve sheath tumors (schwannoma or neurofibroma). The decision was made to take the patient to surgery for a biopsy and potential total
97
resection of the mass. Neuromonitoring was used. After laminectomies were performed, an
98
ultrasound was used to define the mass which appeared solitary and confluent. After the dura
99
was opened, no discrete mass was identified. Rather, multiple roots were grossly enlarged across
100
this segment without obvious mass (Figure 2A&B). Electrical stimulation was used to identify a
101
silent region of the L4 root which was the most abnormal. The pia was sharply incised and tumor
102
forceps were used to remove specimen and debulk the root. Given the benign histology and
103
intimate association of the JXA with eloquent nerve roots, the majority of the mass could not be
104
safely removed. The process was not resectable, a decision was made to sew in an expansile
105
duraplasty (Figure 2C).
M AN U
SC
RI PT
96
Postoperatively the patient had improvement in pain, sensation and strength. No
107
cutaneous sites of disease were noted. She was counseled by hematology-oncology but elected to
108
observe with imaging and not begin chemotherapy at this time. A 3-month follow-up MRI
109
demonstrated postoperative changes with L3-5 laminectomy and partial debulking of intradural
110
enhancing mass. A positron emission tomography (PET)–computed tomography (CT) scan was
111
done that demonstrated active lumbar spinal disease and no other fluorodeoxyglucose (FDG)
112
avid sites of disease.
TE D
106
On the 27-month follow-up clinic visit, the patient was doing well. Her chronic lower
114
back pain and left L4, L5 distribution paresthesia remain well controlled with medication. These
115
symptoms have been present and stable since prior to surgery. She had full motor strength in
116
both lower extremities as well as normal bowel and bladder control. Her MRI lumbar spine has
117
also remained stable throughout this interval without evidence of enlargement or development of
118
new enhancing lesions (Figure 3A-D). She has opted against adjuvant chemotherapy or radiation
119
and continues conservative management with serial imaging and clinical follow up.
AC C
120
EP
113
121 122
Pathology:
123
The lesion was classified as JXG. Chronic inflammatory infiltrates involving a peripheral
124
nerve were seen. Touton giant cells were identified (Figure 4A&B). The infiltrates were
ACCEPTED MANUSCRIPT 5 primarily composed of CD68-positive histiocytes and CD3-positive T cells without atypia
126
(Figure 4C). Approximately 10% of the histiocytes and giant cells were weakly positive for S-
127
100, thought possibly to represent nonspecific staining from phagocytosis of peripheral nerve
128
elements. Emperipolesis was seen in rare foamy histiocytes. No significant numbers of plasma
129
cells or CD20-positive B cells were identified. There was diffuse IgG-immunopositivity but no
130
immunopositivity for IgG4, which ruled out IgG4-related disease. There were no CD1a-positive
131
Langerhans cells. Gram and fungal stains were negative as were stains for spirochetes and AFB.
132
A GFAP immunostain showed no astrocytic or ependymal elements. The MIB-1 proliferation
133
index was <0.1%. A molecular test for the BRAF V600E mutation was negative.
SC
RI PT
125
134
136
M AN U
135 Discussion:
According to a study done by Dehner1 in 2003, the most common presentation of JXG is
138
a solitary skin lesion, and approximately 10% of JXG cases involve extracutaneous sites.
139
Involvement of extracutaneous tissues and organs, and extensive proliferation or malignant
140
transformation can increase morbidity and rarely, mortality rates. In their review of 36 patients,
141
Freyer et al.2 characterized the frequency of extracutaneous sites where JXG manifested as a
142
systemic disease and noted the CNS (8 of 36) and liver/spleen (8 of 36) to be the second most
143
common sites involved after the subcutaneous soft tissue (12 of 36).
144
TE D
137
CNS involvement of JXG4,17-19 is rare, but has been reported all along the neuroaxis. A
146
2013 literature review by Diesch et at.17 noted 38 published reports of JXG in the nervous
147
system, with 75% involving the CNS. The clinical characteristics between CNS and PNS cases
148
differed significantly, but the reported outcomes were similar, with the exception that all three
149
lethal cases involved the CNS. Diesch reported that CNS cases more commonly involved
150
additional cutaneous or extra-nervous disease as compared to PNS cases,17 but Freyer et al.2
151
reported that half of the CNS JXG cases lacked any cutaneous disease. In their 1997 case report
152
and review of the literature, Schultz et al.18 described the clinical presentations of all CNS JXG
153
cases in the literature. Their own case was the first report of a solitary intracranial JXG, and the
154
patient presented with complex partial seizures.18 Later reports of intracranial cases of JXG have
155
demonstrated seizures and focal cranial nerve deficits as common presenting signs.20 Others have
AC C
EP
145
ACCEPTED MANUSCRIPT 6 reported intracranial hypertension,20 elevated anterior fontanelle in an infant,21 incidental
157
discovery,20 and recent onset headaches, blurry vision, cutaneous facial lesions in an adult with a
158
history of diabetes insipidus.22 While less common than solitary lesions, reports of multiple23,24
159
and extensive intracranial JXG lesions25 have been reported, and Tan et al.26 have even described
160
JXG recurrence leading to “diffuse, miliary brain lesions”.26 Leptomeningeal involvement is
161
rare. 2 but has been reported20,23,24,27 and can lead to further intracranial disease or spinal spread.
RI PT
156
162
Kitchen et al.28 described the first JXG lesion of spinal nerve root origin in 1995. Since
164
then, extradural29,30 and intradural31 spinal JXG lesions have been reported. JXG lesions of spinal
165
origin can present with single28 or multiple29 nerve compression and corresponding signs, or
166
spinal cord compression leading to spastic paraparesis31 or acute paraplegia.30 Less commonly,
167
JXG lesions have also been reported in the cauda equina.32,33 Table 1 lists the thoracolumbar
168
JXG cases reported in the literature. In the current report, the patient had no obvious mass, but
169
demonstrated gross enlargement of multiple lumbar nerve roots which lead to significant lower
170
extremity pain and progressing numbness of the legs and weakness in the distal left lower
171
extremity. Preoperative MRI revealed an enhancing mass from L3 to L5 that appeared to fill the
172
foramen at L4/5 on the left, but diagnosis of JXG cannot be made by imaging alone.
M AN U
TE D
173
SC
163
Radiographic findings for JXG are non-specific. Typically, the lesions are isointense on
175
T1-weighted MRI and enhance with gadolinium, but this does not differentiate them from many
176
other masses, including primary tumors or granulomatous disease. Several cases have
177
demonstrated an increased choline signal on MRI, but further studies have identified this
178
phenomenon in other infectious and inflammatory CNS lesions.34 However, Matsubara et al.35
179
and Kwak et al.36 observed elevation of taurine, choline and glutamate, and reduction of N-
180
acetylaspartate in JXG lesions. These findings have only been reported in neuroblastoma and
181
may allow for a more specific differential diagnosis when observed.35
AC C
182
EP
174
183
Because imaging and clinical findings are nonspecific, diagnosis of JXG is dependent on
184
biopsy and histologic findings. The differential diagnosis for histiocytic lesions includes
185
Langerhans cell disease, non-Langerhans cell diseases, and other lesions of infectious, neoplastic
186
or inflammatory origin. These can often be differentiated by immunohistochemical staining
ACCEPTED MANUSCRIPT 7 (IHC). IHC of JXG lesions stains positive for CD68, vimentin, S100 and factor XIIIa, and
188
negative for CD1a, with the presence of classic “Touton giant cells” on histologic
189
examination.1,3,37 As such, Langerhans cell disease can be ruled out by the absence of CD1a
190
molecules that classically stain on their surface. Similar IHC staining and histologic analysis can
191
distinguish between non-Langerhans cell histiocytoses such as Rosai-Dofman disease (RDD) and
192
Erdheim Chester disease (ECD). RDD typically stains positively for S100 and demonstrates
193
emperipolesis, which are both absent in JXG stains.3,17,37 ECD is usually characterized by the
194
BRAF V600E mutation in the inflammatory infiltrates and presents in the sixth decade of life,
195
both of which differentiate it from JXG. In the current report, the biopsy sample was negative for
196
CD1a and BRAF, ruling out Langerhans cell histiocytosis and ECD. While there was some
197
partial S100 staining, this was thought to represent nonspecific staining from phagocytosis of
198
peripheral nerve elements. This, combined with the presence of Touton giant cells and the lack
199
of emperipolesis served to rule out this disease.17 Other pertinent negatives found on analysis
200
were the microbiologic stains, CD20, GFAP, and IgG4, ruling out infectious etiologies, B cell
201
disorders, primary glial cell neoplasms, and IgG4 disease, respectively.
M AN U
SC
RI PT
187
202
JXG is typically a benign disease with many lesions resolving on their own. However,
204
due to disease progression, inability for curative resection, or systemic involvement, multiple
205
deaths have been reported in the literature.1,2,12 JXG disease of the CNS usually follows an
206
indolent course, although rare cases of clinically aggressive JXG involving the CNS have been
207
reported as well, including two deaths reported by Freyer et al.2 Many case reports have
208
individually reported good outcomes with total resection38 and chemotherapy,20 but larger
209
outcome studies are few, and one reported by Wang et al did not reveal any notable associations
210
with good outcomes.19 Complications arising from CNS JXG include sterile brain abscess,36
211
subdural effusion,39 and spread and recurrence of disease.26,27
213
EP
AC C
212
TE D
203
There are currently no established treatment protocols for JXG, though review of the
214
literature supports surgical treatment as a definitive treatment option and possibly curative when
215
a total resection is feasible.38 Although there is more literature about surgery for intracranial
216
JXG, the same pattern seems to apply to spinal JXG as well.31 Of note, Nakasu et al.40 reported
217
on successful implementation of stereotactic radiosurgery for the treatment of intracranial JXG.
ACCEPTED MANUSCRIPT 8 When total resection is not possible, those with systemic or progressive disease should be treated
219
with adjuvant therapy. Reports of success with steroids, vincristine and cladribine have been
220
published,20 and treatment with Langerhans cell multi-agent chemotherapy regimens,
221
immunotherapy, and conventional radiation may also be considered.20 In the current report, the
222
patient elected not to go for adjuvant therapy after subtotal resection and will be followed up
223
with routine imaging.
RI PT
218
224 225
Conclusion
JXG are rare inflammatory lesions that often run an indolent course and may
227
spontaneously involute. However, involvement of the CNS is a poor prognostic factor, and may
228
lead to significant morbidity and even mortality when the disease is progressive, systemic or
229
inaccessible to total surgical resection. Consistent with similar reports in the literature, the
230
authors suggest surgical resection of these lesions with intent to cure. When total resection is
231
infeasible, adjuvant therapy with steroids, chemotherapy, immunotherapy, radiation, and
232
stereotactic radiosurgery should be considered. A patch duroplasty may also provide
233
symptomatic relief of focal compression.
236 237 238 239
Figure Legends
Table 1: Published cases of JXG afflicting the thoracolumbar spine.
EP
235
TE D
234
M AN U
SC
226
Figure 1: Preoperative axial T1 post contrast (A), sagittal T1 post contrast (B), sagittal T1 pre-
241
contrast (C) and sagittal T2 MRI images show a large enhancing intra dural mass centered at
242
L4/5 and extending out the left L4/5 neuroforamen. There is also diffuse thickening and
243
enhancement of multiple lower thoracic and lumbar nerve roots.
244
AC C
240
245
Figure 2: Multiple, grossly enlarged roots were noted without obvious mass (A), stimulation of
246
abnormal roots demonstrated functional conduction to lower lumbar and sacral myotomes (B),
247
expansile duraplasty was performed (C).
248
ACCEPTED MANUSCRIPT 9 Figure 3: Axial T1 post contrast (A), sagittal T1 post contrast (B), sagittal T1 pre-contrast (C)
250
and sagittal T2 MRI images obtained 27 months after surgery show overall stability of
251
previously debulked intra dural enhancing mass centered at L4/5. Again, seen are numerous
252
thickened and enhancing lower thoracic and lumbar nerve roots, which also have not
253
significantly changed.
RI PT
249
254
Figure 4: Chronic inflammatory infiltrate with scattered Touton giant cells (arrows) (H&E) (A),
256
A high-power view illustrating Touton giant cells (arrows). These are multinucleated histiocytes
257
with eosinophilic cytoplasmic areas as well as peripheral foamy, pale-staining cytoplasmic areas
258
(H&E) (B). The Touton giant cells (arrows) were positive for CD68, confirming that they are
259
histiocytes. (Immunohistochemistry) (C).
M AN U
260 261 262
References
EP
TE D
1. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003;27:579-93. 2. Freyer DR, Kennedy R, Bostrom BC, Kohut G, Dehner LP. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996;129:227-37. 3. Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol 2005;29:21-8. 4. Pagura L, de Prada I, Lopez-Pino MA, Huertas JG, Villarejo F. Isolated intracranial juvenile xanthogranuloma. A report of two cases and review of the literature. Childs Nerv Syst 2015;31:493-8. 5. White W, Garen P. Juvenile xanthogranuloma of the paravertebral soft tissue in infancy: a report of two cases. Pediatr Pathol 1991;11:105-13. 6. Shimosawa S, Tohyama K, Shibayama M, Takeuchi H, Hirota T. Spinal xanthogranuloma in a child: case report. Surg Neurol 1993;39:138-42. 7. Allen C MK. Juvenile Xanthogranuloma. 8. Adamson H. Society Intelligence: The dermatologic society of London. Br J Dermatol 1905;17:222. 9. McDonagh J. A Contribution to our Knowledge of the Nevoxanthoendotheliomata. . Br J Dermatol 1912;24:84-9. 10. Helwig EB HV. Juvenile Xanthogranuloma (nevoxanthoendothelioma). Am J Pathol 1954;30:625-6. 11. Azorin D, Torrelo A, Lassaletta A, et al. Systemic juvenile xanthogranuloma with fatal outcome. Pediatr Dermatol 2009;26:709-12.
AC C
263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286
SC
255
ACCEPTED MANUSCRIPT 10
EP
TE D
M AN U
SC
RI PT
12. Hara T, Ohga S, Hattori S, et al. Prolonged severe pancytopenia preceding the cutaneous lesions of juvenile xanthogranuloma. Pediatr Blood Cancer 2006;47:103-6. 13. Hu WK, Gilliam AC, Wiersma SR, Dahms BB. Fatal congenital systemic juvenile xanthogranuloma with liver failure. Pediatr Dev Pathol 2004;7:71-6. 14. Agabegi SS, Iorio TE, Wilson JD, Fischgrund JS. Juvenile xanthogranuloma in an adult lumbar spine: a case report. Spine (Phila Pa 1976) 2011;36:E69-73. 15. Jain A, Mathur K, Khatri S, Kasana S, Jain SK. Rare presentation of juvenile xanthogranuloma in the thoracic spine of an adult patient: case report and literature review. Acta Neurochir (Wien) 2011;153:1813-8. 16. Stover DG, Alapati S, Regueira O, Turner C, Whitlock JA. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008;51:130-3. 17. Deisch JK, Patel R, Koral K, Cope-Yokoyama SD. Juvenile xanthogranulomas of the nervous system: A report of two cases and review of the literature. Neuropathology 2013;33:39-46. 18. Schultz KD, Jr., Petronio J, Narad C, Hunter SB. Solitary intracerebral juvenile xanthogranuloma. Case report and review of the literature. Pediatr Neurosurg 1997;26:315-21. 19. Wang B, Jin H, Zhao Y, Ma J. The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir (Wien) 2016;158:1289-97. 20. Tamir I, Davir R, Fellig Y, Weintraub M, Constantini S, Spektor S. Solitary juvenile xanthogranuloma mimicking intracranial tumor in children. J Clin Neurosci 2013;20:183-8. 21. Sun LP, Jin HM, Yang B, Wu XR. Intracranial solitary juvenile xanthogranuloma in an infant. World J Pediatr 2009;5:71-3. 22. Stepan KO, Sharma A, Chicoine MR, Uppaluri R, Dahiya S. Juvenile xanthogranuloma of supra-sellar region: a rare presentation. Clin Neuropathol;34:368-70. 23. Bostrom J, Janssen G, Messing-Junger M, et al. Multiple intracranial juvenile xanthogranulomas. Case report. J Neurosurg 2000;93:335-41. 24. Chiba K, Aihara Y, Eguchi S, et al. Diagnostic and management difficulties in a case of multiple intracranial juvenile xanthogranuloma. Childs Nerv Syst 2013;29:1039-45. 25. Lalitha P, Reddy M, Reddy KJ. Extensive intracranial juvenile xanthogranulomas. AJNR Am J Neuroradiol 2011;32:E132-3. 26. Tan LA, Uy BR, Munoz LF. Recurrent juvenile xanthogranuloma manifesting as diffuse miliary brain lesions. Br J Neurosurg;28:817-8. 27. Ernemann U, Skalej M, Hermisson M, Platten M, Jaffe R, Voigt K. Primary cerebral nonLangerhans cell histiocytosis: MRI and differential diagnosis. Neuroradiology 2002;44:759-63. 28. Kitchen ND, Davies MS, Taylor W. Juvenile xanthogranuloma of nerve root origin. Br J Neurosurg 1995;9:233-7. 29. George DH, Scheithauer BW, Hilton DL, Fakhouri AJ, Kraus EW. Juvenile xanthogranuloma of peripheral nerve: a report of two cases. Am J Surg Pathol 2001;25:521-6. 30. Wille DA, Bozinov O, Scheer I, Grotzer MA, Boltshauser E. Isolated intraspinal juvenile xanthogranuloma in an infant presenting as acute paraplegia. Neuropediatrics 2013;44:171-3. 31. Kim DS, Kim TS, Choi JU. Intradural extramedullary xanthoma of the spine: a rare lesion arising from the dura mater of the spine: case report. Neurosurgery 1996;39:182-5.
AC C
287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329
ACCEPTED MANUSCRIPT 11
EP
TE D
M AN U
SC
RI PT
32. Castro-Gago M, Gomez-Lado C, Alvez F, Alonso A, Vieites B. Juvenile xanthogranuloma of the cauda equina. Pediatr Neurol 2009;40:123-5. 33. Iwasaki Y, Hida K, Nagashima K. Cauda equina xanthogranulomatosis. Br J Neurosurg 2001;15:72-3. 34. Venkatesh SK, Gupta RK, Pal L, Husain N, Husain M. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging 2001;14:8-15. 35. Matsubara K, Mori H, Hirai N, Yasukawa K, Honda T, Takanashi JI. Elevated taurine and glutamate in cerebral juvenile xanthogranuloma on MR spectroscopy. Brain Dev 2016;38:964-7. 36. Kwak ES, Marrero DE, Pfannl R, Erbay SH. Sterile brain abscess due to juvenile xanthogranuloma: DWI characteristics. J Neuroimaging 2013;23:437-40. 37. Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control 2014;21:322-7. 38. Murphy JT, Soeken T, Megison S, Perez E. Juvenile xanthogranuloma: diverse presentations of noncutaneous disease. J Pediatr Hematol Oncol 2014;36:641-5. 39. Auvin S, Cuvellier JC, Vinchon M, et al. Subdural effusion in a CNS involvement of systemic juvenile xanthogranuloma: a case report treated with vinblastin. Brain Dev 2008;30:164-8. 40. Nakasu S, Tsuji A, Fuse I, Hirai H. Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery. J Neurooncol 2007;84:99-102.
AC C
330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350
Age
Sex
Size
Location
Presenting Signs Imaging Treatment and Symptoms ACCEPTED MANUSCRIPT
Resection
Outcome
White et 5 al. (1991)
3 months
M
4 x 3 x 3 cm
T8; extraspinal, extrathoracic
Mass located on routine physical exam
CT: Non-calcified lesion in paraspinal musculature and subcutaneous tissue with attachment to spinous processes of T7 and T8
Resection and Laminectomy
n/a
No evidence of recurrent disease at 11 months
2 months
M
2 x 1.3 x 1 cm
T7-T8; extraspinal, extrathoracic
Mass located on routine physical exam
MRI: mass in subcutaneous tissue and paraspinal musculature with attachment to spinous processes of T7 and T8
Resection
Shimosawa 6 et al. (1993)
13 months
F
Unspecified
T6-T9 intradural, extramedullary
Mild lower extremity spastic paraparesis
MRI: T1 revealed low-intensity mass on dorsal spinal cord with compression; no enhancement with DPTA
Kitchen et al.28 (1995)
15 years
F
Unspecified
Right S1 nerve root
Chronic low back pain with new radiating right leg pain
No recurrence at 2 years
Laminoplastic laminectomy between T6-T9 with resection
Complete
Significant improvement at 6 months
L5 Laminectomy with resection of sacral hiatus and resection of mass
Complete
Complete resolution of symptoms postop
SC
n/a
M AN U
TE D
CT: expanded S1 nerve root with no enhancement; MRI: T1 mass had the same signal characteristics as nerve; T2 showed increased signal; proton density was same as bone marrow
EP
AC C
RI PT
Citation
ACCEPTED MANUSCRIPT 31
M
18 mm at largest diameter
T1-T2 intradural, extramedullary
Spastic paraparesis
MRI: T1 isointense intradural mass; T2 revealed homogenous enhancement with gadolinium
C7-T3 laminectomy and resection
Agabegi et 14 al. (2001)
47 years
F
Unspecified; “very large”
L2 vertebral body with diffuse extension
Bowel and bladder incontinence; perineal anesthesia; mild R hip flexor weakness
n/a
Pre-operative embolization, decompressive laminectomy T12-L3, spinal stabilization; postoperative radiotherapy
Dehner et 1 al. (2003)
14 years
F
Unspecified
L3
n/a
CastroGago et 32 al. (2009)
14 years
M
Unspecified
L2-L3
Back pain and collapsed vertebrae Lower extremity weakness with occasional pain and paresthesias
15
22 years
F
Unspecified
T7 with left paraspinal and anterolateral epidural soft tissue component
Complete
RI PT
16 months
Unspecified
n/a
Unspecified
Laminectomy at L2-L3
Partial
Decompressive laminectomy and mechanical fixation; complete removal
n/a
Treated with methylprednisolone and prednisone post-op. Initially improved with PT, but symptoms recurred at 12 months. Subsequently treated with prednisone and vinblastine and saw near complete clinical improvement. Resolution of presenting symptoms; 3-month follow up without recurrence
M AN U
SC
Resolution of presenting symptoms at 8 months
MRI: increased signal intensity of cauda equine roots with a string-ofbeads appearance and nodular lesions in posterior spinal canal.
EP AC C
Jain et al. (2010)
Pain in midthoracic region
Significant improvement by 3 months
partial
TE D
Kim et al. (1996)
n/a
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
Highlights - Juvenile Xanthogranuloma are rare, non-Langerhan’s cell histiocytic lesions that primarily present as multiple cutaneous lesions in young males. - Solitary lesions in the spinal column are a particularly rare presentation of this disease.
RI PT
- Treatment strategies vary and may depend on resectability of the tumor, as complete resection may be curative. - Poorly accessible tumors, widespread or progressive disease may require aggressive systemic therapy which may include corticosteroids and vinca alkaloids and/or radiation.
SC
- The efficacy of treatments has not clearly been established yet.
AC C
EP
TE D
M AN U
- A patch duroplasty may also provide symptomatic relief of focal compression.
ACCEPTED MANUSCRIPT
Abbreviations: AFB: Acid-Fast Bacillus CNS: central nervous system CT: computed tomography
RI PT
ECD: Erdheim Chester disease FDG: fluorodeoxyglucose GFAP: Glial fibrillary acidic protein IHC: immunohistochemical staining
SC
JXG: Juvenile Xanthogranuloma
PNS: peripheral nervous system PET: positron emission tomography
AC C
EP
TE D
RDD: Rosai-Dofman disease () and
M AN U
MRI: magnetic resonance imaging